Akademik Veri Yönetim Sistemi
Archives of Dermatological Research, cilt.317, sa.1, 2025 (SCI-Expanded, Scopus)
Isotretinoin, a retinoic acid metabolite, is widely used in the treatment of dermatological conditions, especially acne vulgaris. While its adverse effects on various systems are well-documented, the potential association between isotretinoin and inflammatory bowel diseases (IBD) remains unclear. Fecal calprotectin (FC) serves as a biomarker to differentiate between IBD and functional gastrointestinal disorders, as well as to evaluate intestinal mucosal inflammation. This study aimed to explore the potential link between isotretinoin therapy and intestinal mucosal damage, as well as its possible correlation with IBD, by analyzing FC levels in patients undergoing isotretinoin treatment. A total of 103 patients aged 18–40 years, who were admitted to the Skin and Venereal Diseases outpatient clinic between December 2020 and July 2021, were included in the study. Among them, 65 participants completed the study, and their FC levels were measured both before and after isotretinoin treatment. The results revealed that FC levels increased from a median of 15.6 µg/g prior to treatment to a median of 20.2 µg/g after treatment. In patients with moderate and severe acne vulgaris, the pre-treatment FC levels were 14.1 µg/g and 19.9 µg/g, respectively. However, these changes were not statistically significant. Isotretinoin therapy did not result in a significant change in FC levels in this cohort of adults with moderate-to-severe acne.